| Nov 7 |
Cassava Sciences GAAP EPS of -$0.58 beats by $0.30
|
| Nov 7 |
Cassava Sciences Reports Q3 2024 Financial and Operating Results
|
| Nov 6 |
Cassava Sciences Q3 2024 Earnings Preview
|
| Oct 31 |
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
|
| Oct 30 |
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value
|
| Oct 28 |
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
|
| Oct 18 |
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge
|
| Oct 9 |
Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement
|
| Oct 9 |
Cassava Sciences: Phase III trials storm ahead amid controversy
|
| Oct 8 |
Sector Update: Health Care Stocks Rise Late Afternoon
|
